Tirzepatide · adverse-event profile · research use only
Tirzepatide side effects, as SURMOUNT-1 actually reported them.
Tirzepatide has one of the best-documented adverse-event profiles of any incretin peptide, because the pivotal SURMOUNT-1 obesity trial (NEJM 2022) published its numbers dose by dose. This page reproduces that data as a research reference: the gastrointestinal events that dominate the dual GIP/GLP-1 class, how tightly they track the 5, 10 and 15 mg doses, why they cluster in the escalation weeks, and the specific way this profile differs from semaglutide's — more loose stool, notably less nausea. One honesty note up front: Titan does not stock tirzepatide. It appears here as the reference comparator for the triple-agonist Titan does carry, retatrutide, whose glucagon arm adds effects tirzepatide's two receptors do not. It is a summary of clinical-trial data, not a human-use protocol or medical advice.
GI events dominate — the class signature
In SURMOUNT-1 the most frequent adverse events were gastrointestinal. At the 5/10/15 mg doses respectively, nausea ran 24.6% / 33.3% / 31.0% (vs 9.5% placebo), diarrhea 18.7% / 21.2% / 23.0% (vs 7.3%), constipation ~16.8% / 17.1% / 11.7% (vs 5.8%), and vomiting 8.3% / 10.7% / 12.2% (vs 1.7%). They were generally mild to moderate and usually occurred during the dose-escalation period. GI tolerability is the defining feature of the incretin class, tirzepatide included.
How the three compare →The effect is dose-dependent
A meta-analysis of ten tirzepatide trials put overall GI adverse events at 39% at 5 mg, 46% at 10 mg and 49% at 15 mg — a clear dose gradient — with nausea and diarrhea the most frequent at every dose. Drug discontinuation due to adverse events was highest at 15 mg (around 10% in the pooled analysis; 4.3% / 7.1% / 6.2% across the three doses in SURMOUNT-1 itself versus 2.6% placebo). Serious, fatal, pancreatitis and gallbladder events were all rare (≤1% or low single digits).
See the titration ladder →They cluster in the escalation weeks
As with the whole class, the GI events concentrated during dose escalation and were largely transient — which is why the trials stepped the dose up slowly (the label uses four-week intervals) rather than starting high. A pooled SURMOUNT-1-to-4 analysis confirmed most GI events were non-serious, occurred in the escalation phase, and that weight loss was essentially the same in people who did and did not get GI side effects, meaning the effect is not the mechanism of benefit.
Titration reference →How it differs from semaglutide
Head-to-head data (SURMOUNT-5) shows the two GLP-class agents have distinct GI signatures: semaglutide causes more nausea and constipation, while tirzepatide causes more diarrhea/loose stool with notably less nausea. Discontinuation for side effects was lower on tirzepatide (2.7% vs 5.6% in that trial). The GIP component appears to soften the nausea that a pure GLP-1 agonist produces — a mechanistic difference worth knowing when reading the raw percentages.
Semaglutide side effects →Why the comparator here is retatrutide
Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide — the compound Titan actually stocks — adds a third arm, glucagon-receptor agonism, which brings effects tirzepatide's two receptors do not: a dose-dependent heart-rate rise and dysesthesia (tingling) tied to glucagon activity, on top of the shared GI profile. Reading tirzepatide's table is the cleanest way to see the two-receptor baseline that the triple agonist builds on. This page is not implying Titan sells tirzepatide — it does not.
Retatrutide side effects →Research-use framing
Every figure here describes adverse events observed in human clinical trials of tirzepatide and is reproduced as a research reference for laboratory and in-vitro modelling — not as a prediction of what any individual would experience, and not as instructions for human use. Titan does not supply tirzepatide; the compound is referenced only as a comparator for the in-stock triple agonist retatrutide, which Titan supplies strictly as a research-use-only reagent, not for human or animal consumption. Nothing here is medical advice.
Research-use policy →The detail, in plain terms
The adverse-event table, at a glance.
Rates below are drawn from SURMOUNT-1 (NEJM 2022) at the 5 mg / 10 mg / 15 mg doses versus placebo, plus a ten-trial meta-analysis, reproduced as a research reference. Exact figures vary by study and cohort. Titan does not stock tirzepatide.
- Nausea
- 24.6% / 33.3% / 31.0% (5/10/15 mg) vs 9.5% placebo; peaks mid-ladder, mostly in escalation.
- Diarrhea
- 18.7% / 21.2% / 23.0% vs 7.3% placebo; the event tirzepatide shows more than semaglutide.
- Constipation
- ~16.8% / 17.1% / 11.7% vs 5.8% placebo.
- Vomiting
- 8.3% / 10.7% / 12.2% vs 1.7% placebo; rises with dose.
- All GI AEs (meta-analysis)
- 39% / 46% / 49% across 5/10/15 mg — a clear dose gradient.
- Discontinuation (AE)
- 4.3% / 7.1% / 6.2% vs 2.6% placebo (SURMOUNT-1); ~10% at 15 mg in pooled meta-analysis.
- Serious / fatal / pancreatitis
- Rare — ≤1% to low single digits across doses.
- vs semaglutide
- More diarrhea, less nausea, lower GI discontinuation (2.7% vs 5.6%, SURMOUNT-5).
Questions researchers ask
Before you order.
- What are the most common tirzepatide side effects?
- In SURMOUNT-1 the most frequent were gastrointestinal: nausea (about 25–33% depending on dose vs ~10% placebo), diarrhea (about 19–23%), constipation (about 12–17%) and vomiting (about 8–12%). They were generally mild to moderate and concentrated in the dose-escalation weeks. These are human clinical-trial figures reproduced as a research reference, not medical advice.
- Are tirzepatide's side effects dose-dependent?
- Yes. A ten-trial meta-analysis reported overall gastrointestinal adverse events at 39% at 5 mg, 46% at 10 mg and 49% at 15 mg, with nausea and diarrhea the most frequent at every dose. Discontinuation due to adverse events was highest at the 15 mg dose. This is why the published titration starts low and steps up over four-week intervals rather than starting at the top dose.
- How does tirzepatide differ from semaglutide on side effects?
- Head-to-head SURMOUNT-5 data shows semaglutide causes more nausea and constipation, while tirzepatide causes more diarrhea and loose stool with notably less nausea. Discontinuation for side effects was lower on tirzepatide (2.7% vs 5.6%). The dual GIP/GLP-1 mechanism appears to blunt the nausea that a pure GLP-1 agonist produces.
- Why does this page point to retatrutide instead of tirzepatide?
- Because Titan stocks retatrutide, not tirzepatide. Retatrutide is a triple agonist — it adds glucagon-receptor activity to tirzepatide's dual GIP/GLP-1 profile, which brings additional effects such as a dose-dependent heart-rate rise and dysesthesia on top of the shared GI events. Tirzepatide's well-documented table is the clearest way to understand the two-receptor baseline the triple agonist builds on. This page does not imply Titan sells tirzepatide.
- Is tirzepatide approved for human use?
- Tirzepatide is an FDA-approved drug, but the research-grade material referenced in the peptide market is not a substitute for a prescribed medicine, and Titan does not supply tirzepatide at all. Titan Peptide Lab supplies retatrutide strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption. The adverse-event data here summarises published clinical research and is not medical or dosing advice.